semaglutide compounding fda enforcement news Troubling Findings in Study of GLP-1 Compounders FDA free to pursue semaglutide

Some people adjust quickly, while others notice symptoms for longer

Hypothalamic and brainstem glucose-dependent insulinotropic polypeptide receptor neurons employ distinct mechanisms to affect feeding

Request a call 5-minute readPublished 05/15/2026Updated 11:10 AM EST, 06/08/2026 Sources Medicare GLP-1 Bridge opens in new window , Medicare.gov, last accessed April 24, 2026

WHAT KAISER REQUIRES FIRST Step Therapy Requirements Even in regions where Kaiser covers Zepbound, you must typically "fail" multiple other treatments first: Kaiser Northwest Example (Most Documented) To qualify for Zepbound coverage in Kaiser Northwest, you must demonstrate: [3] Kaiser Zepbound Coverage Criteria BMI 30 (obesity) OR BMI 27 with a comorbidity (hypertension, diabetes, high cholesterol) Age 18+ Following a structured diet and exercise program (documented, not just attested) Failed at least 2 prior weight loss medications : Phentermine Diethylpropion Qsymia (phentermine/topiramate) Contrave (naltrexone/bupropion) Tried semaglutide (Wegovy or Ozempic) for minimum 6 months and either: It was ineffective (didn't achieve target weight loss) Cannot tolerate due to allergy, serious side effects, or contraindication Continuation Requirements (To Keep Coverage) Initial approval typically for 12 months Must document at least 5% weight loss after starting tirzepatide to continue coverage Bariatric medicine chart review required before switching from semaglutide to Zepbound Kaiser's Internal "Medical Weight Management" Program Kaiser often requires patients to enroll in their internal weight management program before approving GLP-1s

Its protective and healing effects on the gastrointestinal lining make it a subject of interest in managing various gastrointestinal disorders

Its role in promoting a balanced internal environment has been widely studied